Wall Street analyst estimates for Caribou Biosciences, Inc. (CRBU): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally.
Valuation Ratios
| Price / Book | 1.25 |
| EV / EBITDA | -1.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $12.4M | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Cost of Revenue | 0 | $34.4M | $984000 | $3.6M | $3.5M | $3.9M | $3.6M |
| Gross Profit | $5.8M | -$22.1M | $8.6M | $10.2M | $31.0M | $6.1M | $7.5M |
| Research & Development | $23.6M | $34.4M | $52.3M | $82.2M | $112.1M | $130.2M | $109.4M |
| Selling, General & Admin | $16.5M | $14.1M | $23.3M | $38.0M | $38.5M | $46.5M | $37.9M |
| Operating Expenses | $40.1M | $14.1M | $75.6M | $116.6M | $147.0M | $172.7M | $143.7M |
| Operating Income | -$34.3M | -$36.1M | -$67.0M | -$106.4M | -$116.1M | -$166.6M | -$136.2M |
| EBITDA | -$30.2M | -$35.2M | -$65.6M | -$95.7M | -$98.4M | -$145.2M | -$145.0M |
| Interest Expense | $4000 | $20000 | $8000 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$31.0M | -$36.1M | -$66.6M | -$99.4M | -$101.9M | -$149.1M | -$148.7M |
| Income Tax | -$7.5M | -$1.8M | $321000 | $70000 | $193000 | -$9000 | -$550000 |
| Net Income | -$23.4M | -$34.3M | -$66.9M | -$99.4M | -$102.1M | -$149.1M | -$148.1M |
| EPS | $-0.85 | $-1.24 | $-1.11 | $-1.64 | $-1.38 | $-1.65 | $-1.59 |
| EPS (Diluted) | $-0.85 | $-1.24 | $-1.11 | $-1.64 | $-1.38 | $-1.65 | $-1.59 |
| Shares Outstanding (Diluted) | $27.7M | $27.7M | $60.3M | $60.8M | $73.8M | $90.3M | $93.4M |
Price
| Price | $1.25 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AARD · ALLO · ENTA · FHTX · HUMA · IVA · OBIO
Explore sector: Healthcare · Biotechnology
More sections of CRBU: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks